A Study to Assess the Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
Launched by VANCE THOMPSON VISION ยท
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether using Kera Sol tears can help reduce the discomfort and symptoms people often experience after LASIK eye surgery, a common procedure to correct vision. The trial focuses on the first two weeks after surgery, a time when many patients may notice temporary eye irritation or dryness, known as Surgical Temporary Ocular Discomfort Syndrome (STODS).
The study is open to adults aged 65 to 74, regardless of gender, who have recently had LASIK surgery. Participants will use Kera Sol tears during the first two weeks after their procedure, and researchers will monitor how well the drops help with symptoms like dryness, irritation, or discomfort. If you or a loved one fits this age group and has had LASIK, joining this study might offer access to a treatment aimed at making recovery more comfortable.
Gender
ALL
Eligibility criteria
About Vance Thompson Vision
Vance Thompson Vision is a leading clinical research organization specializing in advanced ophthalmic care and innovative vision correction therapies. Committed to enhancing patient outcomes, the organization conducts rigorous clinical trials that explore cutting-edge technologies and procedures in the field of ophthalmology. With a team of experienced professionals and a patient-centered approach, Vance Thompson Vision strives to push the boundaries of vision science, providing valuable insights that contribute to the development of transformative treatments for a variety of ocular conditions. Their dedication to research and excellence positions them at the forefront of the vision care industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported